fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Organon launches as new global women’s health company

Written by | 5 Jun 2021

Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell… read more.

Merck Inc. at Organon investor day outlines the vision and plans for the new company

Written by | 14 May 2021

Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women’s health, biosimilars and established brands.The new company will be launched on 3… read more.

Otezla significantly improved measures of disease severity in adults with mild-to-moderate plaque psoriasis – Amgen

Written by | 29 Apr 2021

Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.

FDA approves Kimyrsa to treat acute bacterial skin and skin structure infections (ABSSSI) – Melinta Therapeutics

Written by | 19 Mar 2021

Melinta Therapeutics, LLC announced that the FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by… read more.

Most psoriasis patients taking immunosuppressants survive COVID-19

Written by | 14 Nov 2020

Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry… read more.

Indomethacin for early covid-19

Written by | 22 Oct 2020

Article written by Christine Clark Indomethacin reduces the severity and duration of covid-19 symptoms and the need for hospital admissions

Immuno suppressing drugs do not increase risk for COVID-19

Written by | 25 Sep 2020

Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their… read more.

Bimekizumab superior to Cosentyx in achieving complete psoriasis skin clearance. UCB

Written by | 24 Jul 2020

UCB announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational IL-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Cosentyx (secukinumab)… read more.

Leo Pharma files at FDA a BLA for tralokinumab to treat moderate-to-severe atopic dermatitis.

Written by | 12 Jul 2020

LEO Pharma A/S, a global leader in medical dermatology, announced that the Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD)… read more.

Ferring to market the prefilled syringe formulation of Cimzia in the US for the treatment of Crohn’s disease. UCB + Ferring

Written by | 10 Jul 2020

UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of Cimzia (certolizumab pegol) in the United States, specifically… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.